TP53 mutation in allogeneic hematopoietic cell transplantation for de novo myelodysplastic syndrome.

•76% of patients with de novo myelodysplastic syndrome had at least one mutation.•TP53 mutations were present in 11.4% of the patients.•TP53 mutations were associated with poor outcomes after transplantation.•Only TP53 mutations were independently associated with shorter survival.•TP53 mutations were also associated with higher relapse.